This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Here’s how one company built its own. Currax Pharmaceuticals was ahead of the curve when it set up a direct access platform for its obesity med. Published July 14, 2025 Amy Baxter Staff Reporter post share post print email license Stock via Getty Images Listen to the article 7 min This audio is auto-generated.
Structuring patient assistance programs as independent non-profit foundations helps pharmaceuticalcompanies reduce regulatory and legal exposure while allowing for more holistic, patient-centered support. Lastly, PAPs that are directly managed by pharmaceuticalcompanies may also struggle with public image issues.
In the case of Mounjaro , the pharmaceuticalcompany Eli Lilly holds a patent for both the medication and its injection delivery device. As a brand-name drug, Mounjaro can cost more than $1,400 per month without insurance. 18 and March 19, 2025, respectively, to continue selling tirzepatide without violating FDA guidelines.
AI in real-world evidence generation AI plays a significant role in RWE generation by automating data extraction from EHRs and insurance claims to provide robust insights into drug performance. Thani Jambulingam, PhD Key Takeaways AI enhances traditional HTA by improving accuracy and efficiency. Serialization 2.0:
Is Nexplanon covered by insurance? | How much does Nexplanon cost without insurance? | How to get Nexplanon without insurance Nexplanon is a brand-name prescription birth control implant that does not contain estrogen. in 2027 and other countries in 2025, when a generic version may be approved.
Is Vyzulta covered by insurance? | How much does Vyzulta cost without insurance? | How to get Vyzulta without insurance Vyzulta is a brand-name prescription eye drop medication that is approved by the Food and Drug Administration (FDA) to reduce eye pressure in people with open-angle glaucoma or high eye pressure.
GlobalData Healthcare June 19, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The oligonucleotide market is well-positioned to drive the next wave of personalised treatment. billion from 2021 to 2025 year-to-date. Credit: Kateryna Kon via Shutterstock. ASOs accounted for more than half ($3.54
Prabhakant Sinha, co-founder of ZS Associates, emphasizes that “companies that can think deeply and act swiftly will turn decision velocity into a source of value creation.” 3 One of Fuld’s clients, a global pharmaceuticalcompany, used AI-driven CI to monitor competitor drug launches.
Robert Barrie June 6, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook US health secretary Robert F Kennedy Jr. In one of the fierier remarks from the roundtable, RFK Jr said: “At every level, doctors, other providers, our hospitals, the pharmaceuticalcompanies, the insurancecompanies, all make money by keeping us sick.
GlobalData Healthcare June 25, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The future Alzheimer’s disease treatment paradigm is anticipated to be combinatorial. The momentum in acquisition activity continued into 2025, with total deal value reaching $16.8 Credit: JLStock via Shutterstock.
Abigail Beaney June 25, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The EHDS has come into force but it has not yet been fully rolled out, with EU member states still in discussions over how the legislation will work. One of the two panels on EHDS at HLTH Europe 2025. Image credit: Abigail Beaney / GlobalData.
Approximately 30% of global data volume is generated by the healthcare industry and it will continue to expand with a compound annual growth rate predicted to reach 36% by 2025, according to research by RBC Capital Markets. It flows from every direction in torrents to create huge opportunities to address the world’s mounting health issues.
Although 5G is currently limited to large cities in developed countries, by around 2025, we can expect its reach will extend beyond the urban areas. Let’s explore how this technology impacts insurancecompanies, healthcare providers (HCPs), pharma content , and pharmaceutical brands.
James Kirby, PharmD, BCPS, FAPhA, is PQAs Board Chair for 2025. I still oversee program development today but am now focused on health care innovation and collaborating with payers, pharmaceuticalcompanies, providers, and patients to bring these holistic solutions to market. We say what we do, and we do what we say.
Compounded semaglutide is made by special compounding pharmacies rather than pharmaceuticalcompanies. The cost of semaglutide can vary on whether youre getting a brand-name or compounded version and whether you have insurance coverage. A monthly supply of semaglutide ranges from about $129$1,850 without insurance.
24 Hours in the Hub Still Matters More June 16, 2025 By Chris Dowd, ConnectiveRx Commentary Article Pharmaceutical Commerce Pharmaceutical Commerce - June 2025 Volume 20 Issue 3 Doubling down on patient access and support fundamentals will win out over Washington’s next move. Chris Dowd Key Takeaways Speed is Critical.
July 10, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Zentiva will manage commercial activities primarily within Europe and CIS markets, excluding the US and Canada. Credit: Zentiva Group, a.s. Sign up for our daily news round-up! Give your business an edge with our leading industry insights.
Source: [link] Demonstrating value Pharmaceuticalcompanies are expected to go beyond simply proving that their treatments work they need to show that their products provide real, measurable benefits for both patients and healthcare systems. How Does the HEOR Model Work for PharmaceuticalCompanies?
Uruguay’s new left-wing coalition government took office in March 2025, under President Yamandu Orsi. The government therefore is advocating for the creation of the new drug regulatory agency to expedite economic growth, streamline drug approvals and attract international pharmaceuticalcompanies to invest in the country.
Source: Deloitte Combining these types of health data allows pharmaceuticalcompanies to understand a person’s health and genetic profile better, thereby improving the quality of healthcare products and services. Pharma companies deal with enormous amounts of health data. What Is Health Data Management?
Because Stelara is expensive without insurance, averaging $37,052 per syringe, you may want to know if there is a generic available that can help save money. There have been several biosimilars approved, including Wezlana , Selarsdi, and Pyzchiva, but they are not expected to be available until early 2025. What is a biosimilar?
The pharmaceuticalcompany Prasco currently markets a generic version of Farxiga. Additionally, several other companies have tentative FDA approvals, meaning that their generic versions have met the requirements for FDA approval but cannot yet be marketed in the United States due to patent issues. How much is generic Farxiga ?
That’s why many Medicare and health insurance plans cover the drug. This law enables Medicare to negotiate directly with pharmaceuticalcompanies, which should ultimately result in lower prescription drug costs for consumers. Under the new law, there will also be a Part D out-of-pocket price cap of $2,000 starting in 2025.
Fortunately, most Medicare and commercial insurance plans cover Jardiance. Original Medicare Parts A and B provide health insurance for inpatient and outpatient health services respectively, among other services. With Medicare coverage, the average patient can expect to pay up to $20 monthly for Jardiance.
Made by the pharmaceuticalcompany Janssen Biotech, Inc., Stelara is an injectable prescription medication used to treat plaque psoriasis , psoriatic arthritis , Crohn’s disease , and ulcerative colitis. It works on proteins that affect the immune system, which helps improve symptoms such as inflammation.
For branded pharmaceuticalcompanies, the impact may be less immediate due to their larger profit margins. However, in the long term, increased costs could be passed on to healthcare systems, insurers, and ultimately, patients. Internet] Beckers Hospital Review 2025. appeared first on European Pharmaceutical Review.
Robert Barrie June 25, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook RFK Jr has embarked on a mission to reset vaccine regulation and evidence generation in the US. In May 2025, he said that all new vaccines would need to be developed without using mRNA technology. Credit: Novikov Aleksey via Shutterstock.
Robert Barrie and Ross Law June 10, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The removal ACIP members marks the most significant upheaval to the current vaccine landscape under Trump’s administration. lev radin via Shutterstock. Give your business an edge with our leading industry insights.
Robert Barrie June 27, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The list price for a month’s supply of 2.4mg Wegovy – the drug’s highest does – is $1,350 in the US, whereas the same dose in the UK costs £175.80 each month. “I Mochi Health is even the subject of a lawsuit initiated by Eli Lilly.
Leyla Hasanzadeh June 18, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Tech transfer for manufacturing purposes in India will be difficult if Trump imposes import duties on pharmaceuticals. The next few weeks of June and July 2025 will be pivotal for their trade relationship as negotiations enter advanced stages.
Robert Barrie June 11, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Drugmakers have poured billions of dollars into pharma manufacturing facilities across the US as they adapt to macroeconomic pressures. Novartis, Eli Lilly, and Genentech have also made US investment announcements in the wake of Trump’s reforms.
Abigail Beaney July 9, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook US President Trump had previously suggested 25% tariffs on the pharmaceutical sector. Find out more This is significantly higher than the 25% tariff threatened by the US President in March 2025. Login Registration is disabled.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content